Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
Geert Leroux‐Roels(Ghent University Hospital), Sylvain Fleury(Cosmetics Europe), Morgane Bomsel(Centre National de la Recherche Scientifique), Frank van Engelenburg, Mario Amacker(University of Bern), Anick Chalifour, Cathy Maes(Ghent University Hospital), Frédéric Clément(Ghent University Hospital), Lucia Lopalco(Vita-Salute San Raffaele University), Michael Adler, Marieke van den Dobbelsteen
Cited by 77
Related Papers
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328
Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges
|Immunity|2011|285
Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.
|PubMed|1991|247
Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells
|The Journal of Immunology|2000|244